Publications by authors named "Jamie S Philp"
Article Synopsis
- The Nix-TB clinical trial tested a new 6-month TB treatment called the BPaL regimen, which includes bedaquiline, pretomanid, and linezolid, achieving a 90% cure rate in drug-resistant TB patients, but caused severe side effects due to linezolid.
- Researchers propose substituting linezolid with inhaled spectinamide 1599 to create the BPaS regimen, which shows similar effectiveness as the BPaL regimen while reducing adverse events.
- In animal studies, the BPaS regimen demonstrated equivalent bactericidal effects with fewer side effects like weight loss and anemia compared to BPaL, suggesting inhaled spectinamide has a superior safety profile in
